Open Access
Acute kidney injury in patients treated with immune checkpoint inhibitors
Shruti Gupta
1, 2
,
Samuel A. P. Short
3
,
Meghan E. Sise
4, 5
,
Jason M Prosek
6, 7
,
Sethu M. Madhavan
6, 7
,
Maria Jose Soler
8, 9
,
Marlies Ostermann
10, 11
,
Sandra M. Herrmann
12, 13
,
Ala Abudayyeh
14, 15
,
Shuchi Anand
4, 16
,
Ilya Glezerman
17, 18
,
Shveta S. Motwani
19
,
Naoka Murakami
1, 2
,
Rimda Wanchoo
20, 21
,
David I Ortiz Melo
4, 22
,
Arash Rashidi
23, 24
,
Ben Sprangers
4, 25, 26, 27
,
Vikram Aggarwal
28, 29
,
A. Bilal Malik
4, 30
,
SEBASTIAN LOEW
31, 32
,
Christopher A Carlos
33, 34
,
WEI TING CHANG
35, 36, 37, 38, 39, 40
,
Pazit Beckerman
41, 42
,
Zain Mithani
43, 44
,
Chintan V. Shah
45, 46
,
Amanda D. Renaghan
4, 47
,
Sophie De Seigneux
48, 49
,
Luca Campedel
50, 51
,
Abhijat Kitchlu
4, 52
,
Daniel Sanghoon Shin
53, 54
,
Sunil Rangarajan
55, 56
,
Priya Deshpande
33, 57
,
Gaia Coppock
58, 59
,
Mark Eijgelsheim
60, 61
,
Harish Seethapathy
4, 5
,
Meghan A. Lee
4, 5
,
Ian A. Strohbehn
4, 5
,
Dwight H. Owen
62, 63
,
Marium Husain
62, 63
,
Clara Garcia Carro
8, 9, 64
,
Sheila Bermejo
8, 9
,
Nuttha Lumlertgul
4, 10, 65, 66
,
Nina Seylanova
10, 65, 67, 68
,
Lucy Flanders
69, 70
,
Busra Isik
12, 13
,
Omar Mamlouk
14, 15
,
JIANQING LIN
14, 15
,
Pablo Garcia
4, 16
,
Aydin Kaghazchi
71, 72
,
Yuriy Khanin
20, 21
,
Sheru K Kansal
23, 24
,
Els Wauters
26, 27, 73, 74
,
Sunandana Chandra
75, 76
,
Kai M. Schmidt-Ott
31, 32, 77, 78
,
Raymond K. Hsu
33, 34
,
Maria C Tio
1, 2
,
Suraj Sarvode Mothi
1, 2
,
Harkarandeep Singh
1, 2
,
Deborah Schrag
79, 80
,
Kenar D. Jhaveri
20, 21
,
Kerry L. Reynolds
5, 81
,
Frank B. Cortazar
82
,
David N. Leaf
1, 2
1
Division of Renal Medicine
4
Division of Nephrology
6
Division of Nephrology, Department of Internal Medicine
8
Nephrology Department
10
Department of Critical Care & Nephrology
12
Division of Nephrology & Hypertension
14
Divison of Internal Medicine, Section of Nephrology
17
Renal Service
18
20
Division of Kidney Diseases and Hypertension
21
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health
23
Division of Nephrology and Hypertension
24
University Hospital Cleveland Medical Center
25
Department of Microbiology, Immunology and Transplantation, Laboratory of Molecular Immunology (Rega Institute for Medical Research)
28
Department of Nephrology and Hypertension
31
Department of Nephrology and Medical Intensive Care
33
Division of Nephrology, Department of Medicine
35
Institute of Clinical Medicine, College of Medicine
37
Division of Cardiovascular Medicine
38
Chi-Mei Medical Center
39
Department of Biotechnology
41
Institute of Nephrology and Hypertension
42
43
Katz Family Division of Nephrology and Hypertension, Department of Medicine
45
Division of Nephrology, Hypertension, and Renal Transplant, Department of Medicine
48
Service of Nephrology, Department of Medicine
50
Department of Medical Oncology
51
Assistance Publique - Hopitaux de Paris
53
Division of Hematology-Oncology, VAGLAHS, Department of Medicine
55
Division of Hematology/Oncology and Division of Nephrology
58
Renal-Electrolyte and Hypertension Division
60
Department of Internal Medicine, Division of Nephrology
62
Division of Medical Oncology, Department of Internal Medicine
64
San Carlos Clinical University Hospital
65
Guy’s and St Thomas Hospital
67
Sechenov Biomedical Science and Technology Park
69
Department of Oncology
70
Guy’s & St Thomas Hospital
71
Division of Epidemiology and Population Health
73
Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of Chronic Diseases and Metabolism
74
Department of Pneumology
75
ROBERT H. LURIE COMPREHENSIVE CANCER CENTER
77
Max Delbrück Center for Molecular Medicine
78
Helmholtz Association
79
Division of Population Sciences, Medical Oncology
81
Division of Oncology
82
New York Nephrology Vasculitis and Glomerular Center
|
Publication type: Journal Article
Publication date: 2021-10-10
scimago Q1
wos Q1
SJR: 4.220
CiteScore: 17.8
Impact factor: 10.6
ISSN: 20511426
PubMed ID:
34625513
Cancer Research
Oncology
Pharmacology
Molecular Medicine
Immunology
Immunology and Allergy
Abstract
Background
Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer.
Methods
We collected data on 429 patients with ICPi-AKI and 429 control patients who received ICPis contemporaneously but who did not develop ICPi-AKI from 30 sites in 10 countries. Multivariable logistic regression was used to identify predictors of ICPi-AKI and its recovery. A multivariable Cox model was used to estimate the effect of ICPi rechallenge versus no rechallenge on survival following ICPi-AKI.
Results
ICPi-AKI occurred at a median of 16 weeks (IQR 8–32) following ICPi initiation. Lower baseline estimated glomerular filtration rate, proton pump inhibitor (PPI) use, and extrarenal immune-related adverse events (irAEs) were each associated with a higher risk of ICPi-AKI. Acute tubulointerstitial nephritis was the most common lesion on kidney biopsy (125/151 biopsied patients [82.7%]). Renal recovery occurred in 276 patients (64.3%) at a median of 7 weeks (IQR 3–10) following ICPi-AKI. Treatment with corticosteroids within 14 days following ICPi-AKI diagnosis was associated with higher odds of renal recovery (adjusted OR 2.64; 95% CI 1.58 to 4.41). Among patients treated with corticosteroids, early initiation of corticosteroids (within 3 days of ICPi-AKI) was associated with a higher odds of renal recovery compared with later initiation (more than 3 days following ICPi-AKI) (adjusted OR 2.09; 95% CI 1.16 to 3.79). Of 121 patients rechallenged, 20 (16.5%) developed recurrent ICPi-AKI. There was no difference in survival among patients rechallenged versus those not rechallenged following ICPi-AKI.
Conclusions
Patients who developed ICPi-AKI were more likely to have impaired renal function at baseline, use a PPI, and have extrarenal irAEs. Two-thirds of patients had renal recovery following ICPi-AKI. Treatment with corticosteroids was associated with improved renal recovery.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
2
4
6
8
10
12
|
|
|
CKJ: Clinical Kidney Journal
11 publications, 6.08%
|
|
|
Journal of Clinical Medicine
8 publications, 4.42%
|
|
|
Journal of Onco-Nephrology
8 publications, 4.42%
|
|
|
Advances in Kidney Disease and Health
7 publications, 3.87%
|
|
|
Journal for ImmunoTherapy of Cancer
4 publications, 2.21%
|
|
|
Cancers
4 publications, 2.21%
|
|
|
Frontiers in Immunology
4 publications, 2.21%
|
|
|
Renal Failure
4 publications, 2.21%
|
|
|
Nature Reviews Nephrology
3 publications, 1.66%
|
|
|
Kidney Medicine
3 publications, 1.66%
|
|
|
Seminars in Nephrology
3 publications, 1.66%
|
|
|
Clinical journal of the American Society of Nephrology : CJASN
3 publications, 1.66%
|
|
|
Kidney International
3 publications, 1.66%
|
|
|
Kidney International Reports
3 publications, 1.66%
|
|
|
Kidney360
3 publications, 1.66%
|
|
|
Journal of Clinical Investigation
2 publications, 1.1%
|
|
|
Current Opinion in Nephrology and Hypertension
2 publications, 1.1%
|
|
|
International Journal of Clinical Oncology
2 publications, 1.1%
|
|
|
International Journal of Molecular Sciences
2 publications, 1.1%
|
|
|
Diagnostics
2 publications, 1.1%
|
|
|
Frontiers in Medicine
2 publications, 1.1%
|
|
|
Intensive Care Medicine
2 publications, 1.1%
|
|
|
Clinical and Experimental Nephrology
2 publications, 1.1%
|
|
|
Nefrologia
2 publications, 1.1%
|
|
|
BMC Nephrology
2 publications, 1.1%
|
|
|
Interdisciplinary Cancer Research
2 publications, 1.1%
|
|
|
European Journal of Cancer
2 publications, 1.1%
|
|
|
Bulletin du Cancer
2 publications, 1.1%
|
|
|
Cureus
2 publications, 1.1%
|
|
|
2
4
6
8
10
12
|
Publishers
|
5
10
15
20
25
30
35
40
|
|
|
Elsevier
40 publications, 22.1%
|
|
|
Springer Nature
26 publications, 14.36%
|
|
|
MDPI
23 publications, 12.71%
|
|
|
Oxford University Press
16 publications, 8.84%
|
|
|
SAGE
11 publications, 6.08%
|
|
|
Taylor & Francis
9 publications, 4.97%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
9 publications, 4.97%
|
|
|
Frontiers Media S.A.
9 publications, 4.97%
|
|
|
BMJ
7 publications, 3.87%
|
|
|
S. Karger AG
5 publications, 2.76%
|
|
|
American Society of Nephrology
4 publications, 2.21%
|
|
|
Wiley
3 publications, 1.66%
|
|
|
Cold Spring Harbor Laboratory
3 publications, 1.66%
|
|
|
American Society for Clinical Investigation
2 publications, 1.1%
|
|
|
Society for Translational Oncology
1 publication, 0.55%
|
|
|
American Association for Cancer Research (AACR)
1 publication, 0.55%
|
|
|
Georg Thieme Verlag KG
1 publication, 0.55%
|
|
|
Research Square Platform LLC
1 publication, 0.55%
|
|
|
Public Library of Science (PLoS)
1 publication, 0.55%
|
|
|
American Chemical Society (ACS)
1 publication, 0.55%
|
|
|
Royal Society of Chemistry (RSC)
1 publication, 0.55%
|
|
|
IOS Press
1 publication, 0.55%
|
|
|
AMO Publisher
1 publication, 0.55%
|
|
|
PeerJ
1 publication, 0.55%
|
|
|
American Medical Association (AMA)
1 publication, 0.55%
|
|
|
SciELO
1 publication, 0.55%
|
|
|
5
10
15
20
25
30
35
40
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
181
Total citations:
181
Citations from 2024:
87
(48.07%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Gupta S. et al. Acute kidney injury in patients treated with immune checkpoint inhibitors // Journal for ImmunoTherapy of Cancer. 2021. Vol. 9. No. 10. p. e003467.
GOST all authors (up to 50)
Copy
Gupta S. et al. Acute kidney injury in patients treated with immune checkpoint inhibitors // Journal for ImmunoTherapy of Cancer. 2021. Vol. 9. No. 10. p. e003467.
Cite this
RIS
Cite this
BibTex (up to 50 authors)
Copy
@article{2021_Gupta,
author = {Shruti Gupta and Samuel A. P. Short and Meghan E. Sise and Jason M Prosek and Sethu M. Madhavan and Maria Jose Soler and Marlies Ostermann and Sandra M. Herrmann and Ala Abudayyeh and Shuchi Anand and Ilya Glezerman and Shveta S. Motwani and Naoka Murakami and Rimda Wanchoo and David I Ortiz Melo and Arash Rashidi and Ben Sprangers and Vikram Aggarwal and A. Bilal Malik and SEBASTIAN LOEW and Christopher A Carlos and WEI TING CHANG and Pazit Beckerman and Zain Mithani and Chintan V. Shah and Amanda D. Renaghan and Sophie De Seigneux and Luca Campedel and Abhijat Kitchlu and Daniel Sanghoon Shin and Sunil Rangarajan and Priya Deshpande and Gaia Coppock and Mark Eijgelsheim and Harish Seethapathy and Meghan A. Lee and Ian A. Strohbehn and Dwight H. Owen and Marium Husain and Clara Garcia Carro and Sheila Bermejo and Nuttha Lumlertgul and Nina Seylanova and Lucy Flanders and Busra Isik and Omar Mamlouk and JIANQING LIN and Pablo Garcia and Aydin Kaghazchi and Yuriy Khanin and others},
title = {Acute kidney injury in patients treated with immune checkpoint inhibitors},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2021},
volume = {9},
publisher = {BMJ},
month = {oct},
url = {https://doi.org/10.1136/jitc-2021-003467},
number = {10},
pages = {e003467},
doi = {10.1136/jitc-2021-003467}
}
Cite this
MLA
Copy
Gupta, Shruti, et al. “Acute kidney injury in patients treated with immune checkpoint inhibitors.” Journal for ImmunoTherapy of Cancer, vol. 9, no. 10, Oct. 2021, p. e003467. https://doi.org/10.1136/jitc-2021-003467.
Profiles